Ad scientiam
14
3
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
2 terminated/withdrawn out of 14 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Role: lead
Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
Role: lead
Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care
Role: lead
MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience
Role: lead
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
Role: lead
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
Role: lead
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
Role: lead
Descriptive Analysis of Real-world Data Collected with ME&MGopen
Role: lead
A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
Role: lead
Major Depressive Disorder: Early Prediction of Non-response to Antidepressant Therapy Via a Mobile Digital Scale
Role: lead
Impact of a Digital Solution (CardiCare™) on Cardiorespiratory Fitness Improvement in Patients Discharged From a Phase 2 Cardiac Rehabilitation Following an Acute Coronary Syndrome
Role: lead
Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients
Role: lead
Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy
Role: lead
MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment.
Role: lead
All 14 trials loaded